The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook. ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Aquestive Therapeutics, Inc. and its officers and directors [1]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is currently facing scrutiny regarding its New Drug Application (NDA) for Anaphylm, as the FDA has identified deficiencies that prevent further discussions on labeling and post-marketing commitments [3]. - Following the announcement of the FDA's findings, Aquestive's stock price experienced a significant decline, falling by $2.30 per share, or 37.04%, closing at $3.91 per share on January 9, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, is leading the investigation into the claims against Aquestive [1][4]. - The firm has a long history of advocating for victims of securities fraud and has successfully recovered multimillion-dollar damages for class members [4].

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025... ...

Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline https://t.co/XU9FDRmdUb ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market. ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a supplemental application to produce a new specification (0.1g) of the injectable drug Cytarabine, expanding its product line and enhancing market competitiveness [1][4]. Group 1: Drug Information - The drug approved is Cytarabine for injection, with a new specification of 0.1g, which is a chemical drug registered under the approval number H20269025 [1]. - Cytarabine is used for the induction and maintenance treatment of acute non-lymphocytic leukemia in adults and children, and it is effective against other types of leukemia as well [2]. - The company had previously obtained a registration certificate for the 0.5g specification of Cytarabine in March 2025, with a projected domestic market sales amount of approximately RMB 306 million for 2025 [2]. Group 2: R&D Investment - The company has invested approximately RMB 8.17 million in the research and development of the Cytarabine project to date [3]. Group 3: Impact on the Company - The approval of the 0.1g specification is considered equivalent to passing a consistency evaluation, which will enrich the company's product line and improve its market competitiveness [4].

Core Insights - Sanofi (SNY) announced that its late-stage study of venglustat for treating type 3 Gaucher disease (GD3) met all primary and most secondary endpoints [1][9] Group 1: Study Overview - The phase III LEAP2MONO study evaluated the safety and efficacy of once-daily oral venglustat compared to intravenous enzyme replacement therapy (ERT) in 43 patients aged 12 years and older with GD3 [2] - Primary endpoints included assessing changes in neurological function using the modified Scale for Assessment and Rating of Ataxia (SARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) from baseline to week 52 [2] Group 2: Study Results - The study met both primary endpoints, showing statistically significant and clinically meaningful improvements in neurological symptoms at 52 weeks compared to ERT [3] - Venglustat performed comparably to ERT on non-neurological outcomes such as spleen and liver volume and hemoglobin levels, which were important secondary endpoints [4] Group 3: Safety and Tolerability - Venglustat was well-tolerated with no new safety concerns observed, although mild side effects such as headache, nausea, spleen enlargement, and diarrhea were noted [4] Group 4: Regulatory and Market Context - Following the successful phase III data, Sanofi is proceeding with global regulatory filings for venglustat to treat GD3 [5] - Currently, there are no approved treatments for GD3, highlighting the potential market opportunity for venglustat [10] Group 5: Competitive Landscape - Sanofi's commercial portfolio for treating Gaucher disease includes two globally marketed drugs, Cerezyme and Cerdelga, which offer enzyme replacement and oral treatment options, respectively [13]

Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts had expected as the drugmaker prepares for the loss of exclusivity of several of its medicines. MSD reported Q4 global sales of $16.4bn, a 5% increase from the same period in 2024. Full-year sales in 2025 grew 1% to reach $65bn. While year-end results outperformed consensus analyst expectations, investor buoyancy was overshadowed by the 2026 sales forecast. The big pharma company an ...

Core Insights - Merck (MRK) reported Q4 2025 adjusted EPS of $2.04, exceeding the Zacks Consensus Estimate of $2.03, with a 19% year-over-year increase [1] - Q4 revenues rose 5% year-over-year to $16.40 billion, surpassing the Zacks Consensus Estimate of $16.19 billion [1][10] Sales Performance - Keytruda generated $8.37 billion in Q4 sales, a 5% increase, driven by strong uptake in earlier-stage indications and metastatic indications, beating the Zacks Consensus Estimate of $8.31 billion [3] - Alliance revenues from Lynparza and Lenvima contributed to oncology sales, with Lynparza revenues increasing 4% to $389 million and Lenvima revenues totaling $272 million, up 6% [4] - Welireg recorded sales of $220 million, up 37%, benefiting from higher demand in the U.S. and launch uptake in Europe [5] - HPV vaccine sales (Gardasil and Gardasil 9) fell 35% to $1.03 billion due to lower demand in China and Japan, narrowly missing the Zacks Consensus Estimate of $1.04 billion [6] - Capvaxive, a newly launched pneumococcal vaccine, generated $279 million in sales, while Bridion injection sales reached $499 million, up 11% [7] - Januvia/Janumet franchise sales rose 3% to $501 million, driven by higher net pricing in the U.S. [8] Full-Year Results - Full-year 2025 sales increased 1% to $65.01 billion, surpassing the Zacks Consensus Estimate of $64.80 billion, with pharmaceutical sales also growing 1% to $58.10 billion [12] - Adjusted earnings for 2025 were $8.98 per share, a 17% year-over-year increase, beating the Zacks Consensus Estimate of $8.95 per share [12] 2026 Guidance - Merck's 2026 revenue guidance is projected between $65.5 billion and $67.0 billion, falling short of the Zacks Consensus Estimate of $67.36 billion [13] - Adjusted EPS is expected to be between $5.00 and $5.15, significantly lower than the Zacks Consensus Estimate of $6.20 per share, including a one-time charge of $9 billion related to the acquisition of Cidara Therapeutics [14] - The adjusted gross margin is anticipated to be around 82% [14] Market Reaction - Despite strong Q4 results, investor sentiment was dampened by the weak 2026 guidance, leading to a decline in stock price during pre-market trading [17] - Over the past six months, Merck's shares have increased by 42.4%, outperforming the industry average increase of 26.4% [17] Pipeline and Future Outlook - Merck's late-stage pipeline has nearly tripled in the past three years, positioning the company for several new product launches over the next five years [19] - The company is also pursuing external growth opportunities through mergers and acquisitions to diversify its product lineup [19]